Osmotica Pharmaceuticals plc to Present at 2019 Wells Fargo Healthcare Conference
|Date:||Thursday, September 5, 2019|
|Time:||11:30 a.m. Eastern Daylight Time|
|Location:||Westin Copley Place, Boston, MA|
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.
Osmotica has a late‑stage development pipeline highlighted by two NDA candidates that recently completed Phase III clinical trials: arbaclofen ER for spasticity in multiple sclerosis patients and RVL‑1201 for the treatment of acquired blepharoptosis, or droopy eyelid.
Osmotica has operations in
Investor and Media Relations for
In-Site Communications, Inc.
Source: Osmotica Holdings US LLC